Von Eschenbach Is Likely Nominee For Permanent FDA Commissioner
This article was originally published in The Gray Sheet
FDA Acting Commissioner and National Cancer Institute Director Andrew von Eschenbach will likely be nominated by President George W. Bush as the permanent head of the agency, former FDA Associate Commissioner for External Relations Peter Pitts said March 9
You may also be interested in...
After a week of speculation as to who will succeed US FDA Commissioner Scott Gottlieb when he steps down next month, Health and Human Services Secretary Alex Azar announced during a congressional hearing that National Cancer Institute Director Ned Sharpless will step in as acting commissioner. One note of medtech interest in Sharpless' bio: he was a co-founder of a diagnostics company.
Andrew von Eschenbach's role in supporting the development of imaging and other diagnostic technology as director of the National Cancer Institute could inform his approach to medical device regulatory issues as he takes on the added role of acting FDA commissioner
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner